316 related articles for article (PubMed ID: 20142592)
21. Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy.
Smith DA; Conkling P; Richards DA; Nemunaitis JJ; Boyd TE; Mita AC; de La Bourdonnaye G; Wages D; Bexon AS
Cancer Immunol Immunother; 2014 Aug; 63(8):787-96. PubMed ID: 24770667
[TBL] [Abstract][Full Text] [Related]
22. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
Nagaraj NS; Washington MK; Merchant NB
Clin Cancer Res; 2011 Feb; 17(3):483-93. PubMed ID: 21266529
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
Herbst RS; Johnson DH; Mininberg E; Carbone DP; Henderson T; Kim ES; Blumenschein G; Lee JJ; Liu DD; Truong MT; Hong WK; Tran H; Tsao A; Xie D; Ramies DA; Mass R; Seshagiri S; Eberhard DA; Kelley SK; Sandler A
J Clin Oncol; 2005 Apr; 23(11):2544-55. PubMed ID: 15753462
[TBL] [Abstract][Full Text] [Related]
24. Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer.
Krzakowski M; Bennouna J; Dansin E; Kowalski D; Hiret S; Penel N; Favrel S; Tourani JM
Cancer Chemother Pharmacol; 2014 Feb; 73(2):231-6. PubMed ID: 24220936
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
Murakami H; Tamura T; Takahashi T; Nokihara H; Naito T; Nakamura Y; Nishio K; Seki Y; Sarashina A; Shahidi M; Yamamoto N
Cancer Chemother Pharmacol; 2012 Apr; 69(4):891-9. PubMed ID: 22071596
[TBL] [Abstract][Full Text] [Related]
26. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
[TBL] [Abstract][Full Text] [Related]
27. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
28. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.
Cohen EE; Davis DW; Karrison TG; Seiwert TY; Wong SJ; Nattam S; Kozloff MF; Clark JI; Yan DH; Liu W; Pierce C; Dancey JE; Stenson K; Blair E; Dekker A; Vokes EE
Lancet Oncol; 2009 Mar; 10(3):247-57. PubMed ID: 19201650
[TBL] [Abstract][Full Text] [Related]
29. [Role of erlotinib 100 mg/d in the treatment of advanced adenocarcinoma lung cancer failed to previous chemotherapy].
Shi C; Han B; Gu A; Xiong L; Shen J
Zhongguo Fei Ai Za Zhi; 2011 Jun; 14(6):529-33. PubMed ID: 21645458
[TBL] [Abstract][Full Text] [Related]
30. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer.
Perez-Soler R
Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S20-3. PubMed ID: 15638953
[TBL] [Abstract][Full Text] [Related]
31. Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.
Reckamp K; Gitlitz B; Chen LC; Patel R; Milne G; Syto M; Jezior D; Zaknoen S
Cancer; 2011 Feb; 117(4):809-18. PubMed ID: 20922800
[TBL] [Abstract][Full Text] [Related]
32. A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors.
Padda SK; Krupitskaya Y; Chhatwani L; Fisher GA; Colevas AD; San Pedro-Salcedo M; Decker R; Latz JE; Wakelee HA
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1013-20. PubMed ID: 22160298
[TBL] [Abstract][Full Text] [Related]
33. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
Sugawara S; Oizumi S; Minato K; Harada T; Inoue A; Fujita Y; Maemondo M; Yoshizawa H; Ito K; Gemma A; Nishitsuji M; Harada M; Isobe H; Kinoshita I; Morita S; Kobayashi K; Hagiwara K; Kurihara M; Nukiwa T
Ann Oncol; 2015 May; 26(5):888-894. PubMed ID: 25669832
[TBL] [Abstract][Full Text] [Related]
34. Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations.
Tamiya M; Tamiya A; Shiroyama T; Takeoka S; Naito Y; Omachi N; Kimura Y; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
Invest New Drugs; 2018 Aug; 36(4):608-614. PubMed ID: 29101518
[TBL] [Abstract][Full Text] [Related]
35. Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
Dy GK; Infante JR; Eckhardt SG; Novello S; Ma WW; Jones SF; Huff A; Wang Q; Suttle AB; Ottesen LH; Adjei AA; Burris HA
Invest New Drugs; 2013 Aug; 31(4):891-9. PubMed ID: 23135778
[TBL] [Abstract][Full Text] [Related]
36. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.
Janjigian YY; Azzoli CG; Krug LM; Pereira LK; Rizvi NA; Pietanza MC; Kris MG; Ginsberg MS; Pao W; Miller VA; Riely GJ
Clin Cancer Res; 2011 Apr; 17(8):2521-7. PubMed ID: 21248303
[TBL] [Abstract][Full Text] [Related]
37. Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors.
Soria JC; LoRusso P; Bahleda R; Lager J; Liu L; Jiang J; Martini JF; Macé S; Burris H
Oncologist; 2015 Mar; 20(3):245-6. PubMed ID: 25669662
[TBL] [Abstract][Full Text] [Related]
38. Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.
Brunner AM; Costa DB; Heist RS; Garcia E; Lindeman NI; Sholl LM; Oxnard GR; Johnson BE; Hammerman PS
J Thorac Oncol; 2013 Nov; 8(11):1434-7. PubMed ID: 24128713
[TBL] [Abstract][Full Text] [Related]
39. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
[TBL] [Abstract][Full Text] [Related]
40. BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Gridelli C; Rossi A; Ciardiello F; De Marinis F; Crinò L; Morabito A; Morgillo F; Montanino A; Daniele G; Piccirillo MC; Normanno N; Gallo C; Perrone F
Clin Lung Cancer; 2016 Sep; 17(5):461-465. PubMed ID: 27209164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
